- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Endonovo Therapeutics (OTCQB:ENDV) announced it has filed for a patent in the US for its non-invasive electroceutical technology to treat tissues and organs.
Endonovo Therapeutics (OTCQB:ENDV) announced it has filed for a patent in the US for its non-invasive electroceutical technology used to treat tissues and organs.
As quoted in the press release:
The non-provisional patent application follows the Company’s on-going research and development into the development of a novel class of non-invasive therapeutics known as electroceuticals.
“We are very excited about our new generation of non-invasive electroceuticals developed specifically to target vascular diseases and ischemic injuries,” stated Endonovo Chairman and CEO, Alan Collier.
“We believe that this new technology is vastly superior to the original technology, initially developed at NASA, which was higher powered and originally designed for bone healing. Our new signal, which we will be using in our entire pipeline targeting vascular diseases and ischemic injuries, was developed using our scientific team’s twenty plus year experience in researching and developing electrical and bioelectromagnetic therapeutics,” concluded Mr. Collier.
The Company is evaluating the therapeutic potential of its new electroceutical technology in prevention of heart failure following myocardial infarction. The Company now anticipates initial results from its ongoing pre-clinical study in the second quarter of 2017.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a leading developer of bioelectronic-enhanced cell therapies and non-invasive electroceuticals. Endonovo’s Immunotronics™ platform is dedicated to treating patients with vascular diseases and life-threatening inflammatory conditions in vital organs using proprietary non-invasive electroceutical devices. The Company’s non-invasive platform is based on magnetically-induced electrical field pathways that target the disruption of inflammation and cell death.
The Company’s Cytotronics™ platform harnesses the bulk electrical properties of cells and tissues, namely magnetically-induced electrical field pathways to expand and enhance the therapeutic potential of cell therapies and produce next-generation biologics.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.